260 related articles for article (PubMed ID: 31974378)
1. Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells.
Fu S; He K; Tian C; Sun H; Zhu C; Bai S; Liu J; Wu Q; Xie D; Yue T; Shen Z; Dai Q; Yu X; Zhu S; Liu G; Zhou R; Duan S; Tian Z; Xu T; Wang H; Bai L
Nat Commun; 2020 Jan; 11(1):438. PubMed ID: 31974378
[TBL] [Abstract][Full Text] [Related]
2. Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection.
Xiao YS; Gao Q; Xu XN; Li YW; Ju MJ; Cai MY; Dai CX; Hu J; Qiu SJ; Zhou J; Fan J
PLoS One; 2013; 8(8):e70345. PubMed ID: 23940564
[TBL] [Abstract][Full Text] [Related]
3. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
[TBL] [Abstract][Full Text] [Related]
4. Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma.
Cheng X; Tan X; Wang W; Zhang Z; Zhu R; Wu M; Li M; Chen Y; Liang Z; Zhu P; Wu X; Weng X
Cancer Res; 2023 Feb; 83(4):582-594. PubMed ID: 36512635
[TBL] [Abstract][Full Text] [Related]
5. Activation of invariant natural killer T cells by α-galactosylceramide ameliorates myocardial ischemia/reperfusion injury in mice.
Homma T; Kinugawa S; Takahashi M; Sobirin MA; Saito A; Fukushima A; Suga T; Takada S; Kadoguchi T; Masaki Y; Furihata T; Taniguchi M; Nakayama T; Ishimori N; Iwabuchi K; Tsutsui H
J Mol Cell Cardiol; 2013 Sep; 62():179-88. PubMed ID: 23774048
[TBL] [Abstract][Full Text] [Related]
6. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
7. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
Front Immunol; 2019; 10():352. PubMed ID: 30881361
[TBL] [Abstract][Full Text] [Related]
8. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
9. CpG oligonucleotide-mediated co-stimulation of mouse invariant natural killer T cells negatively regulates their activation status.
Kulkarni RR; Villanueva AI; Read LR; Brisbin JT; Bhaumik SK; LaMarre J; Murali-Krishna K; Sharif S
Cell Tissue Res; 2017 Sep; 369(3):541-554. PubMed ID: 28550425
[TBL] [Abstract][Full Text] [Related]
10. Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Scherrer D; Barrett N; Teyton L; Pearce T; Nitcheu J; Pouletty P; Santo J; Ehrlich HJ
Mol Cancer Ther; 2022 Dec; 21(12):1788-1797. PubMed ID: 36198025
[TBL] [Abstract][Full Text] [Related]
11. Spatial distribution of IL4 controls iNKT cell-DC crosstalk in tumors.
Wang L; Liu Z; Wang L; Wu Q; Li X; Xie D; Zhang H; Zhang Y; Gu L; Xue Y; Yue T; Liu G; Ji W; Wei H; Xu T; Bai L
Cell Mol Immunol; 2020 May; 17(5):496-506. PubMed ID: 31160756
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
13. Lactic acid inhibits iNKT cell functions via a phosphodiesterase-5 dependent pathway.
Wang L; Wu Q; Liu J; Zhang H; Bai L
Biochem Biophys Res Commun; 2021 Apr; 547():9-14. PubMed ID: 33588236
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.
Nur H; Rao L; Frassanito MA; De Raeve H; Ribatti D; Mfopou JK; Van Valckenborgh E; De Bruyne E; Vacca A; Vanderkerken K; Menu E
Br J Haematol; 2014 Dec; 167(5):651-63. PubMed ID: 25142285
[TBL] [Abstract][Full Text] [Related]
15. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
Takami M; Ihara F; Motohashi S
Front Immunol; 2018; 9():2021. PubMed ID: 30245690
[TBL] [Abstract][Full Text] [Related]
16. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Invariant Natural Killer T Cells to Skin Wound Healing.
Tanno H; Kawakami K; Ritsu M; Kanno E; Suzuki A; Kamimatsuno R; Takagi N; Miyasaka T; Ishii K; Imai Y; Maruyama R; Tachi M
Am J Pathol; 2015 Dec; 185(12):3248-57. PubMed ID: 26468976
[TBL] [Abstract][Full Text] [Related]
18. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
19. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
20. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
